BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 7543140)

  • 1. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
    Saifuddin M; Parker CJ; Peeples ME; Gorny MK; Zolla-Pazner S; Ghassemi M; Rooney IA; Atkinson JP; Spear GT
    J Exp Med; 1995 Aug; 182(2):501-9. PubMed ID: 7543140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
    Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.
    Nakamura M; Okada H; Sasaki H; Yoshida K; Kamada M; Okada N; Terada M; Ohno T
    Microbiol Immunol; 1996; 40(8):561-7. PubMed ID: 8887350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector.
    Davies A; Morgan BP
    Biochem J; 1993 Nov; 295 ( Pt 3)(Pt 3):889-96. PubMed ID: 7694573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis.
    Saifuddin M; Ghassemi M; Patki C; Parker CJ; Spear GT
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):829-37. PubMed ID: 7527236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).
    Spear GT; Lurain NS; Parker CJ; Ghassemi M; Payne GH; Saifuddin M
    J Immunol; 1995 Nov; 155(9):4376-81. PubMed ID: 7594597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
    Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H
    J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
    Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
    Yuan FF; Bryant JA; Fletcher A
    Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack.
    Amet T; Lan J; Shepherd N; Yang K; Byrd D; Xing Y; Yu Q
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1100-1112. PubMed ID: 27231035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria.
    Shichishima T; Terasawa T; Hashimoto C; Ohto H; Takahashi M; Shibata A; Maruyama Y
    Blood; 1993 Apr; 81(7):1855-62. PubMed ID: 7681703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of the PNH defect by GPI-anchored protein transfer.
    Sloand EM; Maciejewski JP; Dunn D; Moss J; Brewer B; Kirby M; Young NS
    Blood; 1998 Dec; 92(11):4439-45. PubMed ID: 9834251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack.
    Marchbank KJ; Morgan BP; van den Berg CW
    Immunology; 1995 May; 85(1):146-52. PubMed ID: 7543447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
    Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
    Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells.
    Marschang P; Gürtler L; Tötsch M; Thielens NM; Arlaud GJ; Hittmair A; Katinger H; Dierich MP
    AIDS; 1993 Jul; 7(7):903-10. PubMed ID: 7689323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.